Company Search:
Advanced Search
Sponsored Links
Cellectis SA Company Snapshot
Cellectis SA operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Cellectis SA with three other companies in this sector in France: Eurofins-Cerep SA (2018 sales of 25.45 million Euro [US$28.22 million] ), Oncodesign Sa (20.09 million Euro [US$22.27 million] ), and Ose Immunotherapeutics SA (24.46 million Euro [US$27.11 million] ).

Sales Analysis. Cellectis SA reported sales of 18.19 million Euro (US$20.17 million) for the year ending December of 2018. This represents a sharp decrease of 38.5% versus 2017, when the company's sales were 29.60 million Euro. Contributing to the drop in overall sales was the 56.2% decline in Plants, from 802,364.04 Euro to 351,365.94 Euro. There were also decreases in sales in Therapeutics (down 42.9% to 17.84 million Euro) .
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Cellectis SA
  Stock Performance Chart for Cellectis SA
  Stock Data: Recent Stock Performance:
  Current Price (11/29/2019): 12.55
(Figures in Euro)
1 Week 4.1%   13 Weeks 15.6%  
4 Weeks 14.0%   52 Weeks -35.0%  
Cellectis SA Key Data:
  Ticker: ALCLS Country: France
  Exchanges: PAR Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2018 Sales 18,189,553
(Year Ending Jan 2019).
Employees: 149
  Currency: Euro Market Cap: 532,693,146
  Fiscal Yr Ends: December Shares Outstanding: 42,445,669
  Share Type: Action Ordinaires Closely Held Shares: 10,480,419
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.